Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study

被引：0
|
作者：
Andreas Straube
Gregor Broessner
Charly Gaul
Xenia Hamann
Joachim Hipp
Torsten Kraya
Lars Neeb
机构：
[1] University Hospital,Department of Neurology
[2] LMU Munich,Department of Neurology
[3] Innsbruck Medical University,Department of Neurology
[4] Headache Center Frankfurt,Department of Neurology
[5] Teva GmbH,Department of Neurology
[6] Hospital Sankt Georg Leipzig gGmbH,undefined
[7] Headache Center Halle,undefined
[8] University Hospital Halle,undefined
[9] Helios Global Health,undefined
[10] Charité-Universitätsmedizin Berlin,undefined
来源：
The Journal of Headache and Pain | / 24卷
关键词：
Fremanezumab; Calcitonin gene-related peptide; Migraine; Non-responder;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
    Straube, Andreas
    Broessner, Gregor
    Gaul, Charly
    Hamann, Xenia
    Hipp, Joachim
    Kraya, Torsten
    Neeb, Lars
    [J]. JOURNAL OF HEADACHE AND PAIN, 2023, 24 (01):
  • [2] Real-World Effectiveness of Fremanezumab in Patients with Migraine who Switched From Another mAb Targeting the CGRP Pathway (Subgroup Analysis From FINESSE)
    Straube, Andreas
    Broessner, Gregor
    Gaul, Charly
    Hamann, Xenia
    Hipp, Joachim
    Kraya, Torsten
    Schauerte, Isabel
    Neeb, Lars
    [J]. NEUROLOGY, 2023, 100 (17)
  • [3] Real-world effectiveness of fremanezumab in patients with migraine who switched from another mAb targeting the CGRP pathway (subgroup analysis from FINESSE)
    Straube, A.
    Broessner, G.
    Gaul, C.
    Hamann, X.
    Hipp, J.
    Kraya, T.
    Schauerte, I
    Neeb, L.
    [J]. HEADACHE, 2023, 63 : 158 - 159
  • [4] 6-month Real-World Effectiveness of Fremanezumab in Patients with Migraine who switched from another mAb targeting the CGRP pathway (subgroup analysis from FINESSE)
    Straube, Andreas
    Broessner, Gregor
    Gaul, Charly
    Hamann, Xenia
    Hipp, Joachim
    Kraya, Torsten
    Neeb, Lars
    [J]. CEPHALALGIA, 2023, 43 (1supp) : 260 - 260
  • [5] 6-Month Real-World Effectiveness of Fremanezumab in Patients with Migraine who switched from another mAb targeting the CGRP pathway (subgroup analysis from FINESSE)
    Straube, A.
    Broessner, G.
    Gaul, C.
    Hamann, X.
    Hipp, J.
    Kraya, T.
    Neeb, L.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [6] Real-world effectiveness of switching to fremanezumab from other CGRP pathway targeting mAbs: PEARL 3rd interim analysis
    Ashina, M.
    Mitsikostas, D.
    Amin, F.
    Kokturk, P.
    Schankin, C.
    Sahin, G.
    Pozo-Rosich, P.
    Dorman, P.
    Nezadal, T.
    Poole, A.
    Martins, I.
    Sumelahti, M.
    Campos, V. Ramirez
    Ning, X.
    Akcicek, H.
    Tassorelli, C.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 371 - 372
  • [7] Real-world reductions in migraine and headache days after initiating fremanezumab for US patients with migraine and prior use of another monoclonal antibody targeting the CGRP pathway
    Driessen, M. T.
    Patterson-Lomba, O.
    Mu, F.
    Thompson, S. F.
    Seminerio, M. J.
    Carr, K.
    Sun, R.
    Totev, T.
    Yim, E.
    Ayyagari, R.
    Cohen, J. M.
    [J]. HEADACHE, 2021, 61 : 141 - 141
  • [8] REDUCTIONS IN MIGRAINE AND HEADACHE DAYS AFTER INITIATING FREMANEZUMAB FOR PATIENTS WITH MIGRAINE AND PRIOR USE OF ANOTHER MONOCLONAL ANTIBODY TARGETING THE CGRP PATHWAY IN A US REAL-WORLD SETTING
    Driessen, M.
    Patterson-Lomba, O.
    Mu, F.
    Thompson, S.
    Seminerio, M.
    Carr, K.
    Sun, R.
    Totev, T.
    Yim, E.
    Ayyagari, R.
    Cohen, J.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S23 - S23
  • [9] Switching from anti-CGRP-receptor mAb (erenumab) to an antiCGRP-molecule mAbs (fremanezumab) in chronic migraine: results of a real-world study
    Caponnetto, V.
    Hill, B.
    Murphy, M.
    Ighavini, O.
    Briscoe, J.
    Arruda, R.
    Andreou, A. P.
    Lambru, G.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [10] PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine
    Ashina, Messoud
    Amin, Faisal Mohammad
    Kokturk, Pinar
    Cohen, Joshua M.
    Konings, Martijn
    Tassorelli, Cristina
    Lyras, Leonidas
    Mitsikostas, Dimos-Dimitrios
    [J]. PAIN MANAGEMENT, 2021, 11 (06) : 647 - 654
12345